UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

SCHEDULE 13G*

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

(Amendment No. ___)*

 

Y-mAbs Therapeutics, Inc.

 

(Name of Issuer)

 

Common Stock

 

(Title of Class of Securities)

 

984241109

 

(CUSIP Number)

 

August 24, 2018

 

(Date of Event Which Requires Filing of the Statement)

               

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

Cusip No. 984241109 13G Page 2 of 5 Pages

 

 

1.

 

NAME OF REPORTING PERSONS

 

Nai-Kong V. Cheung

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a)     ¨

(b)     ¨

 

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION     United States

 

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

2,426,400

 

6.

 

SHARED VOTING POWER

 

 

 

7.

 

SOLE DISPOSITIVE POWER

2,426,400

 

8.

 

 

SHARED DISPOSITIVE POWER

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON     2,426,400

 

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES ¨

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     8.64%

 

 

12.

 

 

TYPE OF REPORTING PERSON (See Instructions) IN

 

 

       

 

 

 

 

Cusip No. 984241109 13G Page 3 of 5 Pages

 

Item 1(a). Name of Issuer: Y-mAbs Therapeutics, Inc.

 

Item 1(b). Address of Issuer’s Principal Executive Offices: 230 Park Avenue, Suite 3350, New York, NY 10169

 

Item 2(a). Name of Person Filing: Nai-Kong V. Cheung

 

Item 2(b). Address of Principal Business Office or, if none, Residence: 425 E. 58th St., Apt 34D, New York, NY 10022

 

Item 2(c). Citizenship: United States

 

Item 2(d). Title of Class of Securities: Common Stock

 

Item 2(e). CUSIP Number: 984241109

 

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

(a) ¨    Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);

 

(b) ¨    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);

 

(c) ¨    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);

 

(d) ¨     Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

 

(e) ¨   An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

(f) ¨   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

(g) ¨    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h) ¨     A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i) ¨     A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

 

(j) ¨   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k) ¨      Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

 

 

 

 

Cusip No. 984241109 13G Page 4 of 5 Pages

 

Item 4. Ownership:

 

Provide the following information regarding the aggregate number and percentage of class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned: 2,426,400

 

(b) Percent of Class: 8.64%

 

(c) Number of shares as to which such person has:

 

(i) sole power to vote or to direct the vote:

 

2,426,400

 

(ii) shared power to vote or to direct the vote:

 

(iii) sole power to dispose or to direct the disposition of:

 

2,426,400

 

(iv) shared power to dispose or to direct the disposition of:

  

Item 5. Ownership of Five Percent or Less of a Class:

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person: N/A

 

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: N/A

 

Item 8. Identification and Classification of Members of the Group: N/A

 

Item 9. Notice of Dissolution of Group: N/A

  

 

 

 

Cusip No. 984241109 13G Page 5 of 5 Pages

 

Item 10. Certifications:

 

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, I certify (the undersigned certifies) that the information set forth in this statement is true, complete and correct.

 

  8/25/2020
  (Date)
   
  /s/ Nai-Kong V. Cheung
  (Signature)
   
  Nai-Kong V. Cheung
  Name and Title

 

 

Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Y mAbs Therapeutics Charts.
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Y mAbs Therapeutics Charts.